Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis
Background: Approximately 20%–50 % of individuals with autoimmune encephalitis (AE) demonstrate suboptimal responses to first-line therapies, leading to persistent neurological deficits and the need for second-line interventions. Although rituximab has shown potential as an alternative treatment in...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025001276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|